2014-06-02 15:57:30 UTC

Researchers: Collaborate with an International Pharmaceutical Company

June 12, 2014

Are you interested in working with a commercial partner to bring your GI research to life? Researchers are now invited to submit an abstract of ideas, concepts or preliminary data to be considered for a new exceptional opportunity funded by Takeda Pharmaceuticals International, Inc. and the AGA Research Foundation.

Do you have an idea for research collaboration that could yield a new drug or diagnostic relevant to celiac disease or a GI motility disorder, particularly those involving neural/hormonal dysfunction or the gut microbiome?

Researchers are now invited to submit an abstract of ideas, concepts or preliminary data to be considered for a new exceptional opportunity funded by Takeda Pharmaceuticals International, Inc. and the AGA Research Foundation. The most promising will be invited to present their concepts in person at a private conference to be held at Takeda Pharmaceuticals International, Inc. headquarters near Chicago, and may be chosen to work directly with this international company to further develop their promising ideas.

Visit www.gastro.org/discovery for more information and to apply. Applications must be submitted by July 28, 2014, and if selected, candidates must be able to present their ideas to Takeda on Oct. 8, 2014.

This program is funded by Takeda Pharmaceuticals International, Inc. and the AGA Research Foundation.

More on Celiac Disease

The Lowdown on the Low-FODMAP Diet

Nov. 1, 2017

As the low-FODMAP diet grows in popularity, know the facts to help answer patient questions and provide guidance.

Spotlight on Fellow-Led Quality Improvement Projects

Oct. 3, 2017

These 19 projects presented at DDW® 2017 showcase the extensive work being done by fellows to improve the quality of care provided to GI patients.

Avoidance of Cow's Milk–Based Formula for At-Risk Infants Does Not Reduce Development of Celiac Disease: A Randomized Controlled Trial

Oct. 1, 2017

Increased cow's milk antibody titers before the appearance of anti-TG2A and celiac disease indicates that subjects with celiac disease might have increased intestinal permeability in early life.